Valentra Labs runs the HIPAA Security Rule risk analysis as a continuous program — assets, risks, controls, and evidence in one operating record that stays current between audits.
A HIPAA risk analysis filed once a year is stale the day it is signed. When an auditor or the board asks what changed since, a spreadsheet cannot answer, and the next analysis starts from a blank page.
Valentra Labs operates the risk analysis inside the Managed Security Program. Valentra Nexus discovers assets, ranks each risk, ties it to a control and its evidence, and keeps the analysis current as the environment changes — producing a board-ready Decision Packet leadership signs.
What you have
What a point-in-time risk analysis leaves you with.
You have
An analysis that was true the day it was signed.
A spreadsheet of risks, rated once and filed.
But
The environment changed the week after.
No risk ties to its control or its evidence.
“What changed since” has no answer.
What it costs you
What that costs you.
01Audit exposure when the evidence is rebuilt by hand.
02A board that sees a static list, not a trajectory.
03Every cycle restarts from a blank page.
The system
The HIPAA risk analysis, run as one operating record.
Each stage feeds the next, so the analysis stays current between audits instead of resetting each year.
01AssetEvery system and vendor that holds ePHI, discovered and kept current.
02RiskEach risk ranked against the asset it threatens.
03ControlThe safeguard that reduces the risk, owned and operated.
04EvidenceProof the control runs, tied to the control it backs.
05WorkThe remediation that closes the gap, with an owner.
No ramp-up theater. The first month produces visible, measurable progress — by design.
Day 1–10Discover
The systems and vendors that touch ePHI are inventoried and the current analysis is loaded into one operating record.
Day 11–20Operate
Each risk is tied to its control and the evidence that backs it; the open gaps get an owner and a due date.
Day 21–30Report
The first board-ready Decision Packet ships — the analysis, the work in flight, and where risk is trending.
What you get
What you get.
01A current risk analysis
Not a snapshot — an analysis that stays true as the environment changes.
02Evidence tied to every control
Each safeguard carries the proof it runs, ready for an auditor without a scramble.
03A board-ready Decision Packet
The situation, options, recommendation, evidence, and approval chain in one artifact.
04A trajectory, not a snapshot
Risk trending against a target, cycle over cycle — the answer to “what changed since.”
The artifact this produces
Every Valentra Labs program produces the same artifact: a board-ready Decision Packet
carrying the situation, options, recommendation, evidence, and approval chain —
generated by Valentra Nexus.
Decision Packet · v1.0
Q2 2026 — Crown-Jewel Risk Disposition
pkt_2026-04-17_a3f8e1·
Situation
Q2 program review covers the crown-jewel ePHI store and its supporting control envelope. 487 endpoints catalogued across three network segments; 12 unsanctioned SaaS surfaces detected by the shadow-IT scan. Continuous monitoring posture is operating; the residual question is risk acceptance for two compensating-control gaps surfaced this cycle.
Risk & Impact
14 critical findings scored against the revenue-at-risk model. Two compensating gaps (vendor-SOC-2 attestation lapse + patch-cycle #38 awaiting CAB sign-off) carry residual risk of $1.4M in unmitigated regulatory exposure if a HITRUST audit lands before remediation closes. Patient-data confidentiality remains the load-bearing impact dimension.
Options
Accept residual risk through Q3, with quarterly board re-review.
Accelerate remediation by re-prioritizing the patch cycle ahead of the planned Q3 platform migration (cost: 2 engineer-weeks).
Transfer risk via expanded cyber-insurance rider (cost: $48K/yr premium delta; coverage gap on ePHI exfiltration remains).
Recommendation
Pursue Option 2 — accelerate remediation. The 2 engineer-weeks of effort cost is recoverable in Q3; the residual exposure is asymmetric (regulatory floor of $1.4M vs. ~$120K labor delta). Document the patch-cycle re-prioritization as a logged decision with the program owner; close the SOC-2 attestation gap via vendor outreach in the same window. Insurance rider deferred to Q4 review.
Evidence
Twelve evidence artifacts back the recommendation — asset inventory, control mapping, vendor SOC-2 status, residual-risk model, patch-cycle telemetry, and the prior packet's audit trail. One control attestation is overridden with a documented compensating-control narrative; two vendor attestations are pending the Q2 refresh window.
Overridden per compensating-control narrative — see attached
Penetration test report — Q1 follow-up
#a5b6c7d8
stale
—
Prior packet audit trail — pkt_2026-01-09_b8c4e2
#b6c7d8e9
verified
—
Approval Chain
CIO and CISO have signed. The CCO signature is pending receipt of the vendor-SOC-2 refresh; the program owner has logged the override and the compensating-control narrative.
Chief Information OfficerM. AlvarezSigned 2026-04-17T14:08:11Z
Chief Information Security OfficerJ. ParkSigned 2026-04-17T14:18:42Z
The program maps each operating stage — asset, risk, control, evidence, work, decision —
to the frameworks healthcare cybersecurity teams report against. Valentra Nexus carries
the full framework-alignment grid; see how the stages line up on the platform page.
Valentra Labs operates the HIPAA Security Rule risk analysis as a continuous program: Valentra Nexus discovers assets, ranks each risk, ties it to a control and its evidence, and keeps the analysis current between audits — producing a board-ready Decision Packet, not a once-a-year spreadsheet.